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Abstract
Aims The aim of the current study was to evaluate whether tubular markers kidney injury molecule-1 (KIM-1) and N-acetyl-
ß-glucosaminidase (NAG) are related to acute kidney injury (AKI) and severe disease in patients with COVID-19.
Methods and results In this prospective observational clinical trial we examined a cohort of 80 patients with proof of acute 
respiratory infection and divided them into a COVID-19 cohort (n = 54) and a control cohort (n = 26). KIM-1 and NAG were 
measured from urine samples collected in the emergency department. We assessed the development of AKI, admission to 
the intensive care unit (ICU) and intrahospital death as clinical endpoints. Urinary KIM-1 and NAG were not significantly 
different between patients with SARS-CoV-2 and those with other respiratory infections (each p = n.s.). Eight patients from 
the COVID-19 cohort and five of the non-COVID-19-patients suffered from acute kidney injury during their stay. Nine 
COVID-19 patients and two non-COVID-19 patients were admitted to the ICU. KIM-1 was significantly elevated in COVID-
19 patients with, compared to those without AKI (p = 0.005), as opposed to NAG and creatinine (each p = n.s.). Furthermore, 
KIM-1 was significantly elevated in the patients with COVID-19 that had to be transferred to the ICU (p = 0.015), in contrast 
to NAG and creatinine (each p = n.s.).
Conclusion Assessing KIM-1 in patients with COVID-19 might provide additional value in recognizing AKI at an early 
stage of disease. Further, KIM-1 might indicate higher risk for clinical deterioration as displayed by admission to the ICU.
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Introduction
The COVID-19 pandemic is due to the rising number in 
cases of SARS-CoV-2 infection, and the tremendous num-
ber of deaths is a worldwide challenge regarding social as 
well as medical concerns. Limited health care resources 
and rapidly rising cases force us to find objective indica-
tors for those at higher risk of severe disease. This will help 
to guarantee early and adequate medical treatment to those 
patients who need it most. Identifying those factors may help 
to achieve a deeper understanding of the pathophysiology 
of COVID-19 and to discover new ways of, for example, 
pharmacological treatment.
Kidney injury molecule-1 (KIM-1) and N-acetyl-ß-
glucosaminidase (NAG) are both urinary markers of renal 
tubular damage [1, 2]. Previous studies have shown their 
benefit for early detection of acute kidney injury (AKI), out-
performing serum creatinine for that purpose [3, 4]. Beyond 
that, urinary KIM-1 and NAG have been evaluated for their 
prognostic value regarding mortality and rehospitalization in 
patients with chronic heart failure [5]. Recently, KIM-1 was 
Fig. 1  STARD flow diagram of 
the study design
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suggested as receptor for SARS-CoV-2 uptake in alveolar 
and proximal tubule epithelial cells [6].
While SARS-CoV-2 is especially known for its pulmo-
nary manifestations, there is growing evidence of renal 
involvement in COVID-19. Several clinical trials have 
shown that acute kidney injury is highly prevalent and is 
associated with higher mortality rates in patients with 
COVID-19, especially in the critically ill [7–9]. However, it 
is still unknown whether KIM-1 and NAG are related to AKI 
and severe disease in patients with COVID-19 or other acute 
respiratory infections. Because of this, we analyzed a cohort 
of COVID-19 patients in this prospective observational clin-
ical trial. To our knowledge, this is the first study to evaluate 
KIM-1 and NAG in the early stages of COVID-19.
Methods
Study population
Between March 2020 and February 2021, adult patients pre-
senting with acute symptoms of respiratory infection (cough 
and/or fever) to the emergency department (ED) of the Uni-
versity Hospital Regensburg were included. Pre-specified 
exclusion criteria consisted of age below 18 years and the 
inability to understand and sign the declaration of consent. 
The ongoing study was approved by the Ethics Committee 
of the University of Regensburg. It was executed in alli-
ance with the Good Clinical Practice guidelines and within 
the standards established for human experimentation by the 
Declaration of Helsinki.
Every patient was tested for SARS-CoV-2 infection by 
PCR analysis using throat rinse water or a nasopharyngeal 
swab. Patients with negative test results were used as the 
control group (defined as either bacterial or viral respira-
tory infection). The diagnosis at discharge was evaluated 
by a consultant physician to assure the correct distribution 
of patients in the control group. If there was no proof of 
respiratory infection, we excluded the case from analysis 
(n = 10, Fig. 1). A STARD flow diagram of the study design 
is displayed in Fig. 1 [10].
Baseline data, vital signs and findings of clinical exami-
nation were obtained and documented for all patients. To 
estimate the risk of acute clinical worsening we used the 
national early warning score 2 (NEWS-2). We assessed the 
development of AKI, admission to intensive care unit (ICU) 
and intrahospital death as clinical endpoints. The second-
ary endpoint was a composite of acute kidney injury, ICU-
admission and death (defined as event). Acute kidney injury 
was diagnosed in accordance with the 2012 KDIGO criteria 
[11]. Estimated glomerular filtration rate (eGFR) was calcu-
lated by the CKD EPI formula from serum creatinine, sex 
and age [12].
Sample procession and biochemical analysis
Blood and urine samples were collected in the emergency 
department directly after inclusion and sent to the cen-
tral laboratory. Patients for whom urine samples were not 
available were excluded from this analysis (n = 54, Fig. 1). 
Together with the parameters of routine care, NT-proBNP, 
serum and urinary creatinine were measured immediately. 
Proteinuria was measured via turbidimetry with benz-
ethonium chloride, and albuminuria by turbidimetry with 
anti-albumin-antibodies.
Urine samples were aliquoted in 500 µl cups after cen-
trifugation and frozen at − 80 °C for later analysis of tubular 
markers KIM-1 and NAG. For the measurement, all samples 
were thawed at the same time, just before starting the assay, 
after which they were vortexed and centrifuged at 14,000 g. 
For analysis of KIM-1, the ELISA Duo kit and the respec-
tive ancillary reagent kit (R&D Systems, Minneapolis, Min-
nesota, USA) were used as intended in the manufacturer’s 
instructions. The measurement of NAG was performed with 
a modified ELISA-assay in 96-well plates (Roche, Basel, 
Swiss). The wells were infused with 100μL of substrate 
solution and pre-incubated for 5 min at 37 °C. Afterwards, 
5μL of either sample, control or standard was added to the 
plate, mixed carefully for 30 s and incubated for 60 min at 
37 °C. The reaction was then stopped by adding 200μL of 
stop solution. Finally, after incubating for 10 min at 37 °C, 
absorbance was measured at 580 nm. To keep the dilutional 
bias of the urine samples as low as possible, all values of 
KIM-1 and NAG were related to urine creatinine (UCr). Dis-
tortion of the results due to UCr is unlikely as concentrations 
did not differ within the cohorts (each p > 0.05). Values of 
proteinuria and albuminuria were also normalized to urinary 
creatinine.
Statistics
Variables were tested for normal distribution with the Kol-
mogorov-Smirnoff test. Student’s t-test was used for nor-
mally distributed continuous variables. Mann–Whitney-U 
test was utilized for not normally distributed, continuous val-
ues. Categorical variables were analyzed using Chi-square 
test or Fisher’s exact test. All p-values delineated are two 
tailed. Correlation coefficients were calculated according to 
Spearman. Normally distributed data is described as mean 
and standard deviation, whereas not normally distributed 
data is presented as median and interquartile range. To 
visualize differences in biomarker concentrations, boxplots 
were created. Furthermore, ROC analysis was performed 
and AUC and sensitivity, as well as specificity for KIM-1 
and NAG were calculated. Statistical analysis was performed 
using SPSS 27 (SPSS Inc., Chicago, Illinois).
 Journal of Nephrology
1 3
Table 1  Baseline characteristics
Overall collective Controls SARS-CoV-2 Statistics (p)
Baseline characteristics
 n 80 26 54
  Agee (y) 56.8 ± 17.1 60 ± 16.8 55,3 ± 17.2 0.32b
 Sex, % male (n) 66.3 (53) 73.1 (19) 63 (34) 0.37a
 Smokers (continued), % (n) 11.3 (9) 19.2 (5) 7.4 (4) 0.12a
 Intrahospital death, % (n) 5 (4) 3.8 (1) 5.6 (3) 0.74a
 ICU admission, % (n) 13.8 (11) 7.7 (2) 16.7 (9) 0.27a
 Acute Kidney Injury, % (n) 16.3 (13) 19.2 (5) 14.8 (8) 0.62a
 Event (ICU/Death/AKI), % (n) 21.3 (17) 26.9 (7) 18.5 (10) 0.39a
 CT scan, % (n) 87.5 (70) 88.5 (23) 87 (47) 0.86a
 CT scan with CM, % (n) 31.3 (25) 38.5 (10) 27.8 (15) 0.35a
 CM volume in CT  scand (ml) 70 (70–77.5) 70 (70–90) 70 (70–70) 0.92b
Baseline medication, % (n) 70 (56) 69.2 (18) 70.4 (38) 0.74a
 Immunosuppressants, % (n) 11.3 (9) 15.4 (4) 9.3 (5) 0.42a
 Beta-blockers, % (n) 23.8 (19) 20.8 (8) 20.4 (11) 0.31a
 ACE-/AT-1-inhibitors, % (n) 26.3 (21) 26.9 (7) 25.9 (14) 0.92a
 Insulin, % (n) 5 (4) 3.8 (1) 5.6 (3) 0.74a
 Metformin, % (n) 7.5 (6) 11.5 (3) 7.4 (4) 0.54a
 Statins, % (n) 20 (16) 34.6 (9) 14.8 (8) 0.043a
 Diuretics, % (n) 22.5 (18) 26.9 (7) 20.4 (11) 0.51a
 ASS, % (n) 20.8 (16) 29.2 (7) 17 (9) 0.28a
Pre-existing diseases
 Coronary artery disease, % (n) 16.3 (13) 42.3 (11) 3.7 (2) < 0.001a
 Chronic heart failure, % (n) 6.3 (5) 15.4 (4) 1.9 (1) 0.019a
 Arterial hypertension % (n) 45 (36) 57.7 (15) 38.9 (21) 0.11a
 Diabetes mellitus, % (n) 16.3 (13) 23.1 (6) 13 (7) 0.25a
 Obesity, % (n) 26.3 (21) 38.5 (10) 20.4 (11) 0.085a
 COPD, % (n) 5 (4) 15.4 (4) 0 (0) 0.003a
 Asthma, % (n) 2.5 (2) 0 (0) 3.7 (2) 0.32a
 Chronic kidney disease, % (n) 13.8 (11) 15.4 (4) 13 (7) 0.77a
Symptoms
 Cough, % (n) 58.8 (47) 69.2 (18) 53.7 (29) 0.19a
 Dyspnea, % (n) 57.5 (46) 65.4 (17) 53.7 (29) 0.32a
 Fever, % (n) 65 (52) 69.2 (18) 63 (34) 0.58a
 Chills, % (n) 50 (40) 50 (13) 50 (27) > 0.99a
 Fatigue, % (n) 76.3 (61) 65.4 (17) 81.5 (44) 0.11a
 Anosmia, % (n) 12.5 (10) 3.8 (1) 16.7 (9) 0.10a
 Dysgeusia, % (n) 31.1 (25) 19.2 (5) 37 (20) 0.11a
Vital signs
 Heart  ratee (b.p.m.) 90 ± 18.5 96 ± 25 87 ± 14.5 0.096c
 Systolic blood  pressuree (mmHg) 130 ± 18 129 ± 21 130.5 ± 17 0.90c
 Diastolic blood  pressuree (mmHg) 79.5 ± 12.5 79 ± 14 79 ± 12 0.92c
 Oxygen demand, % (n) 41.3 (33) 42.3 (11) 40.7 (22) 0.89a
  Temperaturee(°C) 37.5 ± 0.84 37.54 ± 0.98 37.49 ± 0.78 0.64c
 Respiratory  ratee (/min) 22.5 ± 7 22.5 ± 7 22 ± 7 0.49c
  NEWS2d 4 (1.25–6) 4 (1–6) 3.5 (2–6) 0.72b
Biomarkers
 KIM-1d (ng/g UCr) 1316 (490–2480) 1468 (420–2923) 1316 (485–2316) 0.55b
  NAGd (U/g UCr) 4.75 (1.54–10.7) 5.1 (1.5–13.3) 4.8 (1.5–10.5) 0.75b
 NT-proBNPd (pg/ml) 142 (50–670.25) 393.5 (50–1553.5) 103 (50–508) 0.085b




We included 80 patients in the current study. Among them, 
54 (67.5%) were tested positive for SARS-CoV-2, whereas 
26 (32.5%) were classified as having either bacterial or viral 
respiratory infection. Clinical characteristics are listed in 
Table 1. In both groups, patients were predominantly male. 
The mean age was 56.8 years and did not significantly dif-
fer between the COVID-19 and the control cohort (60 vs. 
55.3 years, p = n.s.). The controls suffered more often from 
chronic heart failure, coronary artery disease and chronic 
obstructive pulmonary disease than the SARS-CoV-2 cohort 
(each p < 0.05). Symptoms, vital signs and NEWS-2 did not 
differ between the two groups (each p = n.s.). Prescription 
of statins was higher among controls (p = 0.043), while the 
other baseline drugs did not differ between the cohorts (each 
p = n.s.).  
Nine (16.7%) patients with COVID-19 were admitted to 
the ICU, three (5.6%) of them died because of the infec-
tion. Regarding the control group, one (3.8%) patient died, 
and two (7.7%) were admitted to the ICU. Eight (14.8%) 
patients from the SARS-CoV-2 group and five (19.2%) of the 
non-COVID-19 patients suffered from acute kidney injury 
during their stay. In total, ten (18.5%) COVID-19-patients 
and seven (26.9%) non-COVID-19 patients suffered from at 
least one of the events considered in the composite endpoint. 
The median interval time between presentation to the emer-
gency department and the occasion of acute kidney injury 
was 4 days in the COVID-19 cohort and 3 days in the control 
cohort. The two patients in the control group and the five 
patients in the COVID-19 cohort were transferred to the ICU 
on the day of hospital admission. The other three COVID-
19 patients were admitted to the ICU between the third and 
the fifth day after hospitalization. The median time between 
hospital admission and death was 13 days in the COVID-
19 cohort. The control patient died only a few hours after 
admission. For further information see also Table 2.
KIM-1 and NAG, as well as serum creatinine, eGFR, 
proteinuria and albuminuria were not significantly different 
between patients with SARS-CoV-2 and those with other 
respiratory infections (each p = n.s.). Interleukin-6 (IL-6) 
as well as white blood cell count were significantly higher 
in the control cohort than in the COVID-19 cohort (each 
p < 0.05). There were no differences between the two cohorts 
regarding CRP and NT-proBNP (each p = n.s.).
KIM-1 was significantly correlated with NAG in the 
COVID-19 cohort (ρ = 0.63, p < 0.001) as well as in the 
control cohort (ρ = 0.66, p < 0.001). Both KIM-1 and NAG 
were significantly negatively correlated with eGFR in the 
ACE angiotensin–converting enzyme; AT-1 angiotensin II receptor type I; CM contrast media; COPD chronic obstructive pulmonary disease; 
CRP C-reactive protein; CT scan computed tomography scan; eGFR estimated glomerular filtration rate; ICU intensive care unit; IL-6 inter-
leukin 6; KIM-1 kidney injury molecule 1; NAG N-acetyl-β-glucoasaminidase; NEWS-2 national early warning score 2; NT-proBNP N-terminal 
prohormone of brain natriuretic peptide
a Fisher´s exact test
b Mann-Whitney-U–test
c Student’s t-test
d Median (interquartile range)
e Mean ± standard deviation;
Table 1  (continued)
Overall collective Controls SARS-CoV-2 Statistics (p)
 Serum  creatinined (mg/dl) 0.95 (0.77–1.26) 0.97 (0.79–1.17) 0.95 (0.76–1.29) 0.68b
  eGFRd (ml/min per  m2) 84 (55–98.5) 81.5 (61.25–97) 86.5 (53.5–100) 0.58b
  Proteinuriad (mg/g UCr) 154 (90–442,5) 148 (87–487) 154 (90.5–416.5) 0.98b
 IL-6d (pg/ml) 36 (13.4–67.6) 59.2 (26.8–260) 24.6 (13.1–60.5) 0.012b
  CRPd (mg/dl) 43.1 (15–77.5) 52.2 (8–85.3) 38.8 (20.55–77) 0.95b
 White blood cell  countd (n/nl) 6.89 (4.69–10.94) 10.6 (7.32–14.88) 5.23 (4.15–8.6) < 0.001b
Table 2  Median interval time (days) between presentation to the ED 
and occurrence of AKI/admission to ICU/death
AKI = acute kidney injury, ICU intensive care unit, ED emergency 
department
a Mann-Whitney-U–test
b Median (interquartile range)
Controls SARS-CoV-2 Statistics (p)
AKIb 3 (1–3) 4 (1–5) 0.52a
ICUb 0 (0–0) 0 (0–3) 0.53a
Deathb 0 (0–0) 13 (8–13) 0.50a
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Fig. 2  Boxplots showing KIM-1, NAG, serum creatinine and eGFR 
of patients with and without AKI in the COVID-19 study cohort (dis-
played in gray color) and the control cohort (white color). A COVID-
19: KIM-1 is significantly elevated in patients who suffer acute kid-
ney injury (†: p < 0.05 vs. no AKI (COVID-19)). Controls: Patients 
with AKI show higher values of KIM-1 without reaching statistical 
significance. B COVID-19/Controls: NAG shows a trend towards 
higher concentrations in patients with AKI. C COVID-19: eGFR 
shows a trend towards lower levels. Controls: eGFR is significantly 
decreased in patients with AKI versus no AKI (‡: p < 0.05 vs. no AKI 
(Controls)). D COVID-19: Creatinine shows a trend towards higher 
values in patients with AKI versus without AKI. Controls: Creatinine 
is significantly elevated in patients reaching the composite endpoint 
(‡: p < 0.05 vs. no AKI (Controls))
Table 3  Median concentration 
and ROC analysis of KIM-1 and 
NAG for detection of AKI, ICU 
admission and the composite 
endpoint in the COVID-19 
cohort
AKI acute kidney injury; ICU intensive care unit; KIM-1 kidney injury molecule-1; NAG N-acetyl-β-
glucoasaminidase; UCr urinary creatinine
a Median
KIM-1 NAG
AKI vs. no AKI
  Concentrationa 2460 vs. 1040 [ng/g UCr] 10.3 vs. 4.4 [U/g UCr]
 ROC analysis
     Cut-off value / sensitivity / specific-
ity
1590 [ng/g UCr] / 87.5% / 65% 7.2 [U/g UCr] / 62.5% / 67.5%
ICU vs. no ICU
  Concentrationa 2195 vs. 1040 [ng/g UCr] 10.7 vs. 3.65 [U/g UCr]
 ROC analysis
  Cut-off value / sensitivity / specific-
ity
1590 [ng/g UCr] / 78% / 64% 7.2 [U/g UCr] / 67% / 69%
ICU/Death/AKI vs no ICU/Death/AKI
  Concentrationa 2235 vs. 934 [ng/g UCr] 9 vs. 4.4 [U/g UCr]
 ROC analysis
     Cut-off value / sensitivity / specific-
ity
1590 [ng/g UCr] / 80% / 66% 7.2 [U/g UCr] / 60% / 68%
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COVID-19 cohort (KIM-1: ρ = -0.43,s NAG: ρ = -0.34, each 
p < 0.05), as opposed to serum creatinine (each p = n.s.). In 
the control cohort, only NAG was significantly negatively 
correlated with eGFR (ρ = -0.45, p < 0.05), in contrast to 
KIM-1 (p = n.s.). Neither KIM-1 nor NAG correlated with 
serum creatinine in the control group (each p = n.s.). KIM-1 
and NAG were significantly correlated with level of pro-
teinuria in the COVID-19 cohort (KIM-1: ρ = 0.54, NAG: 
ρ = 0.68, each p < 0.001) and in the control cohort (KIM-1: 
ρ = 0.61, p < 0.001, NAG: ρ = 0.59, p < 0.05).
Acute kidney injury
Regarding patients with COVID-19, KIM-1 levels were sig-
nificantly higher in patients with, compared to those without 
AKI (p = 0.005, Fig. 2A). NAG showed a not statistically 
significant trend to be elevated in COVID-19 patients suffer-
ing from acute kidney injury (p = 0.086; Fig. 2B).
According to ROC analysis, KIM-1 was able to detect 
acute kidney injury in COVID-19 subjects with an AUC 
of 0.81 (p = 0.006, Fig. 4A). Further information regarding 
ROC analysis can be found in Table 3.
In the COVID-19 cohort there was a not significant 
trend towards higher concentrations of serum creatinine 
and lower values of eGFR in patients with, compared to 
those without AKI (each p = n.s.). Proteinuria and albu-
minuria were significantly higher in COVID-19 patients 
who developed AKI compared to those who did not (each 
p < 0.05, Table 4). Regarding the detection of acute kidney 
injury, ROC analysis showed an AUC of 0.78 for proteinu-
ria and an AUC of 0.73 for albuminuria (each p < 0.05). 
Additional information concerning the ROC analysis is 
presented in Table 5. 
Regarding patients without SARS-CoV-2-infection, 
KIM-1 as well as NAG showed a non-significant trend to 
be higher in patients with AKI (each p = n.s.; Fig. 2A, B). 
Serum creatinine was significantly higher and eGFR sig-
nificantly lower in AKI patients in the control cohort (each 
p < 0.05, Fig. 2C, D).
Admission to the intensive care unit
In patients with COVID-19, KIM-1 was significantly higher 
in patients admitted to the ICU (p = 0.015, Fig. 3A). NAG 
showed a non-significant trend towards higher concentra-
tions in ICU versus non-ICU patients (p = 0.072, Fig. 3B). 
Regarding the prediction of subsequent ICU admission, 
ROC analysis showed an AUC of 0.76 for KIM-1 (Fig. 4B).
KIM-1 was significantly correlated with NEWS-2 in the 
COVID-19 cohort (ρ = 0.457, p = 0.001) as well as in the 
control cohort (ρ = 0.607, p = 0.002), as opposed to NAG 
(each p = n.s.)
In the control cohort, both KIM-1 and NAG showed a 
statistically non-significant trend to be elevated in patients 
who had to be transferred to the ICU (each p = n.s., Fig. 3A 
and B).
In the COVID-19 cohort as well as in the control cohort, 
there was a non-significant trend towards higher concentra-
tions of serum creatinine and lower values of eGFR in ICU 
versus non-ICU patients (each p = n.s.).
Proteinuria and Albuminuria showed a not significant 
trend towards higher values in patients that had to be treated 
in the ICU in both cohorts (p = n.s., Table 4).
Table 4  Proteinuria 
characteristics
AKI acute kidney injury; ICU intensive care unit; UCr Urinary creatinine
a Mann-Whitney-U–test
b Median
Proteinuria [mg/gUCr] Statistics (p) Albuminuria [mg/
gUCr]
Statistics
AKI vs. no AKI
  Controlsb 373 vs. 131 0.41a 193 vs. 37 0.18a
 SARS-CoV-2b 461 vs. 142 0.011a 93 vs. 26 0.04a
ICU vs. no ICU
  Controlsb 1089 vs. 126 0.26 a 768 vs. 41 0.81a
 SARS-CoV-2b 460 vs. 146 0.059 a 90 vs. 26 0.09a
Table 5  ROC analysis of proteinuria and albuminuria for the detec-
tion of AKI in COVID-19 patients
AKI acute kidney injury; ROC receiver operating curve
Proteinuria Albuminuria
Cut-off value 200 [mg/g UCr] 42 [mg/g UCr]
Sensitivity 75% 75%
Specificity 65% 61%
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Fig. 3  Boxplots showing KIM-1 and NAG in patients who were 
admitted to ICU (above) or reached the composite endpoint (below) 
in COVID-19 study cohort (displayed in gray color) and the con-
trol cohort (white color). A COVID-19: KIM-1 is significantly 
elevated in patients who had to be treated in ICU (†: p < 0.05 vs. 
no ICU (COVID-19)). Controls: Patients admitted to the ICU show 
higher values of KIM-1 without reaching statistical significance. B 
COVID-19/Controls: NAG shows a trend towards higher concentra-
tions in patients admitted to ICU. C COVID-19: KIM-1 is signifi-
cantly elevated in patients suffering an event (ICU-admission, Death 
and/or AKI) subsequently to their infection (†: p < 0.05 vs. no event 
(COVID-19)). Controls: KIM-1 shows a statistically not significant 
trend towards higher concentrations in patients suffering an event 
compared to those who don’t. D COVID-19/Controls: NAG shows a 
trend towards higher values in patients suffering an event
Fig. 4  Receiver operating characteristic analysis of urinary KIM-1 
and NAG in COVID-19 cohort. A Predictive values of KIM-1 and 
NAG for AKI vs. no AKI in COVID-19 cohort. Area under the curve 
KIM-1: 0.81 (cut-point of 1590 ng/g UCr: sensitivity: 87.5%, speci-
ficity: 65%, p < 0.001) as well as NAG: 0.69 (p = n.s.). B Predictive 
values of KIM-1 and NAG for ICU vs. no ICU in COVID-19 cohort. 
Area under the curve KIM-1: 0.76 (cut-point of 1590  ng/g UCr: 
sensitivity: 79%, specificity: 64%, p = 0.015) as well as NAG: 0.69 
(p = n.s.). C Predictive values of KIM-1 and NAG for composite end-
point (AKI/ICU-admission/death) in COVID-19 cohort. Area under 
the curve KIM-1: 0.78 (cut-point of 1590 ng/g UCr: sensitivity: 80%, 
specificity: 66%, p = 0.006) as well as NAG: 0.68 (p = n.s.)
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Composite endpoint ICU/Death/AKI
Regarding patients with COVID-19, KIM-1 was observed in 
significantly higher concentrations in patients reaching the 
combined endpoint (= 0.006, Fig. 3C). NAG showed a non-
significant trend towards higher concentrations in patients 
reaching the composite endpoint (p = 0.08, Fig. 3D). Regard-
ing the detection of the composite endpoint, ROC analysis 
showed an AUC of 0.78 for KIM-1 (p = 0.006; Fig. 4C).
KIM-1 and NAG showed a statistically non-significant 
trend to be elevated in patients reaching the composite end-
point in the control group (p = n.s., Fig. 2C).
In the COVID-19 cohort as well as in the control cohort, 
there was a non-significant trend towards higher concen-
trations of serum creatinine and lower values of eGFR in 
patients reaching the combined endpoint (each p = n.s.).
Discussion
In the current study we evaluated the relationship of tubular 
markers KIM-1 and NAG to the severity of disease and the 
occurrence of acute kidney injury in COVID-19 and other 
respiratory infections.
For the first time it has been shown that KIM-1 is signifi-
cantly elevated on the day of hospital admission in patients 
with COVID-19 suffering from acute kidney injury during 
hospitalization. Furthermore, KIM-1 detected following 
AKI in COVID-19 patients with a good predictive value 
and was significantly associated with future admission to 
the intensive care unit with a satisfying predictive value. 
Moreover, we found significantly higher values of KIM-1 in 
patients who reached the composite endpoint, consisting of 
acute kidney injury, ICU admission and death. These find-
ings might provide additional value regarding risk evaluation 
in patients with COVID-19.
Proteinuria and albuminuria were also significantly ele-
vated in COVID-19 patients with later occurrence of AKI, 
which concurs with the findings of previous studies [13, 14]. 
However, compared to proteinuria and albuminuria, KIM-1 
detected subsequent AKI with higher sensitivity and speci-
ficity. Further, KIM-1 showed a trend towards higher AUC 
values in ROC analysis. These findings implicate that KIM-1 
may be superior to proteinuria and albuminuria regarding 
early detection of AKI. One explanation for these findings 
may be that the level of proteinuria is also highly influenced 
by chronic kidney disease and other pre-existing conditions 
[15]. Furthermore, proteinuria is highly prevalent in patients 
with COVID-19, even in those without AKI [16]. However, 
proteinuria and albuminuria did not differ between patients 
with and without COVID-19 in this study.
Furthermore, only KIM-1, but not proteinuria and albu-
minuria, was significantly elevated in COVID-19 patients 
who needed treatment in the ICU compared to those who 
did not. Therefore, KIM-1 may be superior to proteinuria 
and albuminuria regarding risk evaluation in COVID-19.
Due to the small number of patients, we can only put forth 
these hypotheses. Further studies with larger cohorts are 
needed to evaluate the extent to which KIM-1 outmatches 
proteinuria and albuminuria in the detection of AKI and later 
ICU admission in COVID-19.
Detection of acute kidney injury in COVID‑19
Acute kidney injury is highly prevalent in patients with 
COVID-19 and is associated with high mortality rates [7–9]. 
Therefore, the early diagnosis and treatment of acute kid-
ney injury in COVID-19 may be essential to reduce morbid-
ity and mortality rates [17, 18]. Renal function is usually 
assessed by serum creatinine, which predominantly displays 
glomerular function [5]. However, it is a poor indicator for 
tubular function and is subsequently unable to detect acute 
damage, which is mainly located in tubular epithelium [4, 5]. 
Therefore, serum creatinine is considered to be a relatively 
late indicator of AKI, which is neither sensitive nor specific 
for the detection of acute kidney injury [17, 19, 20].
In contrast, tubular markers KIM-1 and NAG are con-
sidered to be early and sensitive indicators of acute kidney 
injury [19, 20]. KIM-1 is a type 1 transmembrane glyco-
protein, mainly expressed in renal tubular epithelium [3, 4]. 
In acute kidney injury, KIM-1 expression is highly upregu-
lated, leading to abundant amounts of KIM-1 in the urine 
[3, 4]. NAG on the other hand is a lysosomal enzyme, which 
is highly prevalent in renal proximal tubule cells [4]. Uri-
nary NAG reflects tubular lesions, as glomerular filtration 
is precluded due to its large molecule mass [4]. In healthy 
individuals, only very small amounts of the tubular markers 
can be found in the urine [3, 4]. KIM-1 is usually detectable 
within 24 h after acute kidney injury [21]. The exact onset 
of NAG increase after AKI is still unclear, but it was found 
to be elevated in children within 6 h after coronary angiog-
raphy [22]. Thus, both markers are able to detect AKI early, 
especially at times where serum creatinine and GFR are still 
unchanged [4]. Tu et al. examined a cohort of severe septic 
patients admitted to the ICU and found that in patients who 
developed AKI, KIM-1 levels were elevated within 6 h of 
ICU admission [23]. Interestingly, the first rise in serum cre-
atinine concentration was detected 24 h later [23]. Regarding 
prognostic value, KIM-1 and NAG were able to predict the 
severity as well as adverse outcomes, such as dialysis and 
death, in patients with AKI [19, 24].
Similar to these findings, the results of the current study 
imply that KIM-1 may be able to predict AKI in patients 
with COVID-19 and that KIM-1 may be superior to NAG 
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for that purpose. However, further research in a larger cohort 
is needed to confirm our findings.
Mechanisms of acute kidney injury in COVID‑19
The exact pathophysiology of acute kidney injury in 
COVID-19 is still not fully understood and presumably an 
interaction of SARS-CoV-2- specific and rather unspecific 
mechanisms [7].
First of all, SARS-CoV-2 uses the ACE2 receptor for cell 
entry, which is highly expressed in the kidneys, especially 
in the apical brush borders of proximal tubules as well as in 
podocytes [25–27]. Beyond that, KIM-1 was suggested to be 
a receptor for SARS-CoV-2, which is also highly expressed 
in proximal tubule cells [6]. Virus incorporation may lead 
to podocyte dysfunction as well as acute proximal tubular 
damage and necrosis, which is concurrent with our find-
ings of significantly elevated KIM-1 levels in COVID-19 
patients with AKI [7]. In contrast, Rossi et al. found neither 
SARS-CoV-2 nor typical viral cytopathic effects in the kid-
ney biopsy of a COVID-19 patient with acute kidney injury 
[28]. Thus, the role of viral tropism in acute kidney injury 
remains unclear and needs further evaluation.
Besides a putative cytopathic effect, the SARS-CoV-
2-induced down regulation of membrane-bound ACE2, 
which degrades angiotensin II to angiotensin (1–7), may 
lead to the accumulation of angiotensin II and subsequently 
to inflammation, vasoconstriction and fibrosis in the kid-
ney [29]. This hypothesis is also strengthened by Su et al., 
who found specific virus-like particles as well as prominent 
ACE2 expression particularly in acutely injured proximal 
tubule cells [30].
Moreover, SARS-COV-2 leads to an excessive release of 
inflammatory cytokines, especially in critically ill patients 
[31, 32]. Particularly IL-6 was found to play a role in the 
pathophysiology of acute kidney injury in earlier studies and 
may contribute to AKI in COVID-19 as well [33]. Interest-
ingly, in the current study IL-6 was significantly higher in 
COVID-19 patients with AKI compared to IL-6 levels in 
those without AKI (data not shown).
There are also a few nonspecific factors that may con-
tribute to AKI in patients with COVID-19. First of all, the 
prescription of nephrotoxic medications, as well as the use 
of radiographic contrast media to detect pulmonary embo-
lism, which is highly prevalent in COVID-19 [7, 34]. In 
the current study, contrast media exposure did not differ 
between the COVID-19 cohort and the control cohort. Fur-
ther, besides two patients in the control cohort and two in the 
COVID-19 cohort who received furosemide prior to AKI, 
no nephrotoxic drugs were prescribed.
Beyond that, kidney congestion due to right heart fail-
ure and renal hypoperfusion due to low cardiac output and 
hypovolemia may also contribute to AKI [17, 18]. However, 
acute heart failure did not relevantly contribute to AKI in 
the current study.
Relevance of tubular markers in COVID‑19
Assessing KIM-1 in patients with COVID-19 might provide 
additional value in recognizing acute kidney injury at an 
early stage of disease. Furthermore, KIM-1 may be helpful 
in identifying high risk patients for serious renal involvement 
in COVID-19. Those patients may benefit from an adapta-
tion in their treatment, for example by avoiding nephrotoxins 
and intensifying surveillance of urine output, volume status 
and other hemodynamic parameters. Consequently, the prob-
ability of a favorable outcome may be enhanced.
However, due to the small number of events in the current 
study cohorts, no reliable Cox or logistic regression model 
for further analysis of the prognostic values of KIM-1 could 
be performed [35, 36]. Therefore, we can only generate these 
hypotheses. Beyond that, high levels of KIM-1 indicate a 
high risk for future admission to the intensive care unit. 
With limited health care resources and huge incidences of 
COVID-19, it is crucial to identify those high-risk patients 
and to guarantee adequate treatment for patients who need 
it the most.
Further research with larger cohorts is urgently needed 
to confirm our findings and evaluate the relevance of the 
tubular markers in COVID-19.
Limitations
Only a small number of patients could be included in our 
study. Especially in the control cohort, the lack of a statisti-
cally significant difference between KIM-1 levels in patients 
who did or did not reach one of the endpoints may be due to 
the small sample size. For the same reason no reliable Cox 
or logistic regression model could be performed. Therefore, 
a larger cohort will be needed to affirm the current data. 
Furthermore, urine sample collection was limited due to 
infection-caused hypovolemia. Also, no renal biopsies were 
performed. Therefore, there is no histopathological con-
firmation of acute tubular injury as displayed by elevated 
KIM-1 levels.
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